Provides clinical validation for ACM Biolab’s Tunable Platform (“ATP™”), ACM Biolab’s proprietary polymer-based delivery platform ACM-001 was well tolerated at the recommended dose levels with no serious adverse events and encouraging early immunogenicity data ACM is in partnering…